Skip to main content
Premium Trial:

Request an Annual Quote

New Products: Lexogen's SENSE Total RNA-seq; Maverix Biomics' Analysis; DNAStar's Lasergene

Premium

Lexogen has launched its SENSE Total RNA-seq Library Prep kit for preparing libraries to sequence total RNA, including non-polyA RNA, on Illumina systems. According to the company, the kit has two major steps: SENSE library generation and library amplification.


Maverix Biomics has added functionality to its RNA-seq pipeline in its Maverix Analytic Platform. The improvements allow scientists to launch Cufflinks and HTSeq/DESeq, in order to compare results side by side.


DNAStar has released Lasergene 12. The new release includes improvements to the sequence alignment tool MegAlignPro, including the MAFFT alignment algorithm, several new analysis and visualization methods, and enhanced phylogenetic tree capability, according to the company.

The Lasergene 12 release also features workflows designed for clinical researchers to analyze gene panels and human exome or whole-genome data.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.